Sight Sciences Inc Stock

$6.51

0.91% yesterday

Nasdaq, Sep 27, 10:00 pm CET

ISIN

US82657M1053

Symbol

SGHT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Overview Dividends Analysts Charts News Strategies

Sight Sciences Inc Stock price

$6.51

-26.99 80.57% 5Y

Nasdaq, Closing price Fri, Sep 27 2024

-0.06 0.91%

ISIN

US82657M1053

Symbol

SGHT

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Medical specialties

Key metrics

Market capitalization	$330.52m
Enterprise Value	$247.37m
P/E (TTM) P/E ratio	negative
EV/FCF (TTM) EV/FCF	negative
EV/Sales (TTM) EV/Sales	3.12
P/S ratio (TTM) P/S ratio	4.16
P/B ratio (TTM) P/B ratio	3.24
Revenue growth (TTM) Revenue growth	-2.60%
Revenue (TTM) Revenue	$79.40m
EBIT (operating result TTM) EBIT	$-51.90m
Free Cash Flow (TTM) Free Cash Flow	$-36.57m
Cash position	$118.18m
EPS (TTM) EPS	$-1.06
P/E forward	negative
P/S forward	4.02
EV/Sales forward	3.01
Short interest	2.89%

As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.

Get Started for Free Today

Sight Sciences Inc Stock Analysis

Unlock Scores for Free

??

7 Analysts have issued a Sight Sciences Inc forecast:

2x Buy

29%

5x Hold

71%

More details on Analyst Estimates Including Price Targets

7 Analysts have issued a Sight Sciences Inc forecast:

Buy

29%

Hold

71%

Analyst Estimates with Stock Price Targets

Financial data from Sight Sciences Inc

Income Statement P&L | Balance Sheet | Cash Flow

Quarter TTM Annually

Jun '24		+/- %
Revenue	79 79	3% 3% 100%
- Direct Costs	11 11	13% 13% 14%
Gross Profit	68 68	1% 1% 86%
- Selling and Administrative Expenses	103 103	13% 13% 129%
- Research and Development Expense	17 17	22% 22% 21%
EBITDA	-51 -51	27% 27% -65%
- Depreciation and Amortization	0.64 0.64	55% 55% 1%
EBIT (Operating Income) EBIT	-52 -52	28% 28% -65%
Net Profit	-52 -52	26% 26% -66%

In millions USD.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Subscribe Now

Sight Sciences Inc Stock News

Neutral

GlobeNewsWire

●

about one month ago

Sight Sciences to Present at the Upcoming Morgan Stanley Global Healthcare Conference

MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference, in New York, NY.

Neutral

Seeking Alpha

●

about 2 months ago

Sight Sciences, Inc. (SGHT) Q2 2024 Earnings Call Transcript

Sight Sciences, Inc. (NASDAQ:SGHT ) Q2 2024 Earnings Conference Call August 1, 2024 4:30 PM ET Company Participants Philip Trip Taylor - Investor Relations Paul Badawi - Co-Founder and Chief Executive Officer Alison Bauerlein - Chief Financial Officer Matthew Link - Chief Commercial Officer Conference Call Participants Thomas Stephan - Stifel Joseph Conway - Needham & Company Felipe Lamar - Cit...

Neutral

GlobeNewsWire

●

2 months ago

Sight Sciences to Report Second Quarter Financial Results on August 1, 2024

MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thur...

More Sight Sciences Inc News

Company Profile

Sight Sciences, Inc. is a medical device company, which engages in the provision of glaucoma implants for treatment of irreversible blindness. It also develops pharmaceuticals, drug delivery systems, and diagnostics for the treatment of ophthalmic conditions. The firms products include viscosurgical system and trabeculotomy instrument. It operates through the Surgical Glaucoma and Dry Eye segments. The Surgical Glaucoma segment includes OMNI Surgical System for use in minimally invasive glaucoma procedures. The Dry Eye segment offers TearCare System and related components. The company was founded by Paul Badawi and David Y. Badawi in 2011 and is headquartered in Menlo Park, CA.

Head office	United States
CEO	Paul Badawi
Employees	214
Founded	2011
Website	www.sightsciences.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now